It is exceptionally difficult to deliver precision psychiatry at scale.

MI combines computer vision, AI and clinically validate psychotherapy, in a single, easy-to-use mobile platform.

Personalisation of mental healthcare via real time measurement of therapy efficacy with a validated digital biomarker of stress.

This solution is 100% MI IP, scales and integrates seamlessly into clinicians’ pre-existing workflows.

Platform licensing to hospitals and payors establishes the critical infrastructure and ease of use that supports rapid prescription and adoption of regulated Class II SaMD interventions.

• World’s most accurate objective quantification of stress from mobile selfie video (>80% accuracy*)
• >2.5 million digital biomarkers data points from >25k individuals from 175 countries.
• Clinically validated therapy

*Al-Jebrni et al., AI-enabled remote and objective quantification of stress at scale. BSPC 2020

• Established clients across three target verticals: Health Systems, Payors, Pharma
• FDA Breakthrough Device Designation pending
• Respected institutional investors

MI is rapidly approaching its next inflection point: FDA clearance. When this comes to pass, valuation will increase and new capital will be raised. Pre A investors guarantee FDA clearance.

Globally, more than 1 in 10 people need mental health therapy. Digital therapies for mental illness will reach $500 billion/yr by 2035. As an early leader, MI aims to capture 10% of this market opportunity as the first in history to achieve precision psychiatry at scale.